Answers are grounded in this paper and cite their sources.
For decades, drug development has relied on a pipeline model characterized by sequential experimentation, population-scale clinical trials, and late-stage validation. This drug development framework has produced transformative therapies but was designed for an earlier era of broadly targeted treatments and large patient populations. As therapies become increasingly individualized there is a need to target specific genetic variants in ultra-rare diseases or molecularly defined subtypes of common conditions and to develop new biomarker-guided treatment strategies. As a result, the mismatch between population-scale evidence infrastructure and patient-specific interventions has grown more pronounced. Addressing this gap requires a structural transition in how biomedical evidence is generated, interpreted, and applied. It also requires new approaches that integrate deep phenotyping from human data, computational modeling, real-world evidence, and adaptive regulatory frameworks. This paper reviews evidence that suggests predictable decision-making under biological uncertainty requires three fundamental shifts: first, a transition from document-based to data-centric infrastructure that enables continuous learning; second, new regulatory frameworks that value mechanistic understanding alongside statistical power; and third, collaborative governance models that align incentives across stakeholders. Regulatory agencies worldwide are increasingly signaling openness to evidentiary approaches directly grounded in human biology. Initiatives at the U.S. Food and Drug Administration and its international counterparts are focusing on real-world evidence, digital health technologies, and model-informed drug development. This reflects a shift toward more continuous and integrated evaluation of therapeutic interventions. Together, these changes point to a broader transformation from pipeline-based drug development toward more integrated, platform-enabled evidence generation. Digital infrastructure can begin to integrate multimodal human data with mechanistic and clinical modeling approaches, such as digital twins, to support continuous, adaptive, and human-centered evaluation of therapeutic interventions. These developments suggest a shift toward platform-enabled evidence generation and cross-sector collaboration in precision medicine.
No takes yet. Share an insight, caveat, or question.
Alucozai et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: